NovaBone Products LLC Release: Independent Clinical Study Suggests NovaBone May Stimulate New Bone Formation On An "Equivalent Basis" Compared To BMP-2 -Bone Morphogenic Potein
10/19/2005 5:12:39 PM
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Feb. 8, 2005--NovaBone Products LLC--
"This independent study suggests that NovaBone(R) can be substituted for, or mixed with, BMP-2, thereby allowing use of a synthetic, less costly material that has been safely implanted in humans more than 700,000 times over 10 years."
Arthur C. Wotiz
President and CEO
NovaBone Products LLC
NovaBone Products LLC announced today that results of an independent clinical study of 20 spine fusion surgery patients showed that the Company's FDA-cleared synthetic bone graft product, NovaBone(R), stimulated new bone formation on an 'equivalent basis' compared to 'BMP-2' (bone morphogenic protein) when each was used in a composite as described below.
comments powered by